Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS)

ConditionCABG
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age50+
SponsorNational University Hospital, Singapore

About this trial

One of the most common major surgeries that older patients undergo is coronary artery bypass grafting surgery (CABG), which is performed in approximately 400,000 patients in the United States each year. CABG invokes a massive surgical stress response, with systemic epinephrine increasing 33-fold and norepinephrine increasing 3-fold. Initially, local tissue injury results in a sterile inflammation, releasing damage-associated molecular patterns (DAMPS). DAMPS activate neutrophils, bringing a cascade of cytokines, complement, and coagulation changes. Activation of nociceptors results in a neurometabolic response involving the sympathetic nervous system and hypothalamus-pituitary axis. This brings about systemic effects including changes in basal metabolic rate, hyperglycemia, lipolysis, negative nitrogen balance, and release of cytokines and complement. Although the surgical stress response is essential for wound healing and is usually self-limiting, an exaggerated response may occur resulting in multiple organ dysfunction.

The acute phase of the surgical stress response is often followed by secondary insults that may be either sterile or pathogen-induced (such as postoperative infection).In the "two-hit" model of surgical stress response, there is an exaggerated response even to minor insults in vulnerable individuals who were primed by the initial stress response. Changes in the microbiome may also occur, developing a "pathobiome" that may enter the systemic circulation. If left unchecked, this second hit may result in the development of systemic inflammatory response syndrome (SIRS) and multi-organ failure.

Chronological ageing changes the innate and adaptive immunity of patients. Biological hallmarks of aging such as genomic instability, mitochondrial damage, glycation of proteins, and cellular senescence all result in increased oxidative stress and systemic inflammation. Aging brings about a pro-inflammatory innate immune responsiveness that often occurs even in the absence of an inflammatory threat. This is termed inflammaging. Paradoxically, inflammaging is associated with an increased risk of infection and poor response to stressful events. At the same time, there is an age-associated loss of T-cell function, particularly in naïve CD8 T-cells. This deficit is termed immunosenescence and is characterised by reduced pathogen recognition, chemotaxis, and phagocytosis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Scheduled for elective CABG with cardiopulmonary bypass

Aged 50 years and above

Adequate cognitive function to be able to give informed consent

Disqualifiers

Patients already taking AKG as a supplement

Substance abuse disorder either untreated or treated

Post-traumatic stress disorder, bipolar disorder, Schizophrenia, or any other untreated or poorly controlled mental health or mood disorder, or history of hospitalization due to mental health condition in the past 3 years, cognitively impaired patients

HIV/AIDS

Trial design

Design model

Parallel

Treatments tested in this trial

  • Alpha-ketoglutarate

    Dietary supplement

    Alpha-ketoglutarate supplements

  • Placebo

    Dietary supplement

    Placebo tablets

Treatment groups

250 Participants
are divided into 2 treatment groups
Group A: AKGExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Composite of systemic inflammatory response syndrome (SIRS) and at least 1 organ system

The primary outcome will be a composite of systemic inflammatory response syndrome (SIRS) and at least 1 organ system dysfunction in the systems below. * SIRS; and * Cardiovascular dysfunction; and/or * Neurologic dysfunction; and or * Renal dysfunction; and/or * Respiratory dysfunction; and or * Coagulation dysfunction

Time frame
Postoperative till day 90

Secondary outcomes

1

Other Clinical Outcomes which may be impacted by AKG - Muscle Mass

* Circumferential measurements of arms and calves in cm * Triceps fold thickness in cm

Time frame
Postoperative till day 90
2

Other Clinical Outcomes which may be impacted by AKG - Muscle Strength

• Hand grip strength in kg

Time frame
Postoperative till day 90
3

Other Clinical Outcomes which may be impacted by AKG - Infections Acquired

* Surgical site infection: observational \& charting review * Hospital-acquired infection: observational \& charting review

Time frame
Postoperative till day 90
4

Other Clinical Outcomes which may be impacted by AKG - Long-term Outcomes

* Inflammation * Cardiac * Neurological * Renal Long-term Outcomes will be determined by charting reviews to determine if there are failure of the above listed organ systems

Time frame
Postoperative till day 90

Other outcomes

1

Changes in Immune Status

Comparison between study groups for changes, if any, in gene expression levels using peripheral blood transcriptomics

Time frame
Postoperative till day 90
2

Changes in Gut Microbiome

Comparison between study groups for changes, if any, in gut microbiome via shotgun sequencing to identify microbiome population pre-AKG, pre-op and post-op.

Time frame
Postoperative till day 90
3

Impact of AKG on Cardiometabolic Status

Comparison between study group for changes in cardiometabolic status using metabolic profiling to elucidate the pathway(s) of AKG and ischemic cardio protection.

Time frame
Postoperative till day 90
4

Investigations into Immune Dysregulation and Inflammation

Multiomics platform will be used to identify underlying pathways involved in immune dysregulation and inflammation, if any, and how these pathways are affected by the consumption of AKG pre- and post- operation.

Time frame
Postoperative till day 90

Sponsors and contacts

Click on the lead sponsor to view all of their trials.